Drug Trial Radar · NCT03142139
Does Timeliness of DTaP-IPV-Hib Vaccination Affect Development of Atopic Dermatitis Before 1 Year of Age?
Last checked: Nov 19, 2026Latest source record: May 9, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,027,559
Actual
Start
Jan 1, 1997
Primary completion
Dec 31, 2014
Study completion Dec 31, 2014
Sponsor
- Lead sponsor
- Bandim Health ProjectAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Murdoch Childrens Research Institute
- First posted
- May 5, 2017
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 24 months, up to 24 months
Summary
As written by the sponsor on the registry.
It has been found that the non-live vaccine against Diphtheria, Tetanus, and Pertussis (DTP) in addition to its disease specific effects may have so called "non-specific effects" with the potential to affect sensitivity towards vaccine unrelated pathogens, resulting in excess mortality(Aaby, Kollmann, \& Benn, 2014). A recent study from Australia found that delayed vaccination with the first dose of Diphtheria, Tetanus, and acellular Pertussis(DTaP)-containing vaccine is associated with reduced risk of atopic dermatitis (aOR: 0.57; 95% CI: 0.34-0.97, P = 0.04) and reduced use of medication against atopic dermatitis (aOR: 0.45; 95% CI: 0.24-0.83, P = 0.01)(Kiraly et al., 2016). This register based observational study aims to extend the existing knowledge on non-specific effects of non-live vaccines by testing the above finding, that delayed vaccination with Diphtheria, Tetanus, acellular Pertussis - Inactivated Polio vaccine - Haemophilus influenzae type b (DTaP-IPV-Hib) is associated with lower risk of developing atopic dermatitis before 1 year of age in the Danish birth cohorts from 1997-2012.
Conditions
- Atopic Dermatitis
Interventions
RQ1a: Delayed vs. timely vaccination with the 1st dose of DTaP-IPV-HibBiological
Children will be categorized as "timely vaccinated" if they receive the 1st dose within the month of scheduled vaccination: * "timely vaccinated": received 1st dose of DTaP-IPV-Hib before 4 months of age * "delayed vaccinated": did not receive the first dose of DTaP-IPV-Hib before 4 months of age.
RQ1b: Delayed vs. timely vaccination with the 2nd dose of DTaP-IPV-HibBiological
Children will be categorized as "timely vaccinated" if they receive the 2nd dose within the month of scheduled vaccination: * "timely vaccinated": received 2nd dose of DTaP-IPV-Hib before 6 months of age * "delayed vaccinated": did not receive the 2nd dose of DTaP-IPV-Hib before 6 months of age.
RQ2: Vaccination with DTaP-IPV-Hib compared to being unvaccinatedBiological
• Vaccination status will be assessed as a time dependent exposure, whereby children will be categorized as "unvaccinated" until date of vaccination where they will shift exposure group to "vaccinated".
Primary outcomes
What the sponsor says the trial is designed to measure.
- Atopic dermatitis (AD)Time frame: RQ1.a+ 1.b: Registered AD from baseline until 12 months of age. RQ2: AD is assessed from baseline (3 months of age) through follow-up (until 8 months of age)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.